Royalty Pharma (RPRX) furnishes Q3 2025 results via 8-K filing

Royalty Pharma plc furnished an Item 2.02 Form 8-K announcing its financial results press release for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/05/2025 - 07:31 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Royalty Pharma plc furnished an Item 2.02 Form 8-K announcing its financial results press release for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and the Cover Page Inline XBRL is listed as Exhibit 104.

The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Royalty Pharma (RPRX) disclose in this Form 8-K?

It furnished a press release announcing financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which Form and Item were used for the disclosure by RPRX?

The company used a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Is the press release considered filed or furnished?

It is furnished and not deemed filed under Section 18 of the Exchange Act, and not incorporated by reference unless expressly stated.

What exhibits are included with this 8-K?

Exhibit 99.1 (press release dated November 5, 2025) and Exhibit 104 (Cover Page Inline XBRL).

What securities does RPRX list and where are they traded?

RPRX lists Class A Ordinary Shares on The Nasdaq Stock Market LLC under the ticker RPRX.

Who signed the report for Royalty Pharma?

It was signed by Terrance Coyne, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FALSE000180276800018027682025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

Royalty Pharma plc

(Exact Name of Registrant as Specified in its Charter)

England and Wales			001-39329			98-1535773
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Identification No.)

110 East 59th Street
New York, New York			10022
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (212) 883-0200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Class A Ordinary Shares, par value $0.0001 per share

RPRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On November 5, 2025, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.			Description
99.1			Press release issued by Royalty Pharma plc, dated November 5, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ROYALTY PHARMA PLC
Date: November 5, 2025			By:			/s/ Terrance Coyne
						Terrance Coyne
						Chief Financial Officer